Cantor Fitzgerald Remains Bullish on Heron Therapeutics (HRTX) Following NDA Acceptance
Tweet Send to a Friend
Cantor Fitzgerald analyst, Brandon Folkes, reiterated an Overweight rating and $55.00 price target on Heron Therapeutics (NASDAQ: HRTX) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
